AI Analysis Of CT Scans Finds 42.9% Of Patients Have Coronary Inflammation

TL;DR

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

• Fast, free delivery on millions of items
• Prime Video, Amazon Music and more included
• Member-only deals all year

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

A U.S. study by Biograph using Caristo Diagnostics’ AI analysis of coronary CT angiograms found elevated coronary inflammation in 42.9% of participating asymptomatic adults classified as low risk. The company also reported that standard blood markers and a cardiovascular risk calculator did not identify which participants had inflammation; the findings need further validation and do not establish that the inflammation predicts future disease.

Biograph says a U.S. study using Caristo Diagnostics’ AI analysis of coronary CT angiography found elevated inflammation around the coronary arteries in 42.9% of participating asymptomatic adults considered low risk. The company said the finding was not identified by routine blood tests or a commonly used cardiovascular risk calculator, but the results do not yet show whether the detected inflammation predicts future heart disease.

The study combined high-resolution coronary computed tomography angiography (CCTA) with cardiometabolic testing and Caristo’s CaRi-Heart and CaRi-Plaque technologies. Biograph said participants were asymptomatic and had no known heart disease. The study was available to clinically eligible members of the clinic’s Black tier; the supplied announcement does not state how many people took part or provide detailed participant demographics.

According to Biograph, 42.9% of participants had elevated coronary inflammation, while 17.9% had very high inflammation in at least one major heart artery. The company also reported that about 47% of participants with no detectable coronary plaque had elevated perivascular inflammation. These are findings in the study group, not estimates that can automatically be applied to the broader population.

Biograph said routine measures—including ApoB and non-HDL cholesterol, HbA1c, high-sensitivity C-reactive protein and the AHA PREVENT-ASCVD risk calculator—did not correlate with inflammation in the study or identify the affected participants. The result concerns an AI-derived measure of inflammation around coronary arteries on CT scans; it does not mean that 42.9% of participants had a blockage, a heart attack or diagnosed coronary disease.

What the CT Finding May Add

The reported result points to a possible gap between traditional cardiovascular risk assessment and a measure of inflammation derived from coronary imaging. If later studies establish that the measure reliably predicts outcomes, it could help researchers examine whether some people classified as low risk have signs that warrant closer clinical attention. For now, the study describes detection, not proof that screening for inflammation improves health.

The finding among participants without visible plaque is one reason the result has drawn attention: it suggests the AI measurement may capture information not apparent from plaque or blockage assessment alone. But an imaging signal is not itself a diagnosis or a treatment recommendation. Clinicians and patients would need evidence about how accurately the measure predicts events, what should be done when it is elevated, and whether acting on it improves outcomes.

The distinction matters for readers because the headline percentage refers to a particular study population assessed with a specific technology. It should not be interpreted as the prevalence of coronary inflammation among all adults, nor as evidence that routine blood testing is generally ineffective. The announcement reports no comparison of health outcomes between people with and without elevated inflammation.

How the AI Measure Was Used

Biograph describes the work as its first U.S. study using CaRi-Heart to assess coronary inflammation in asymptomatic, low-risk individuals. CCTA produces images of the coronary arteries. CaRi-Heart analyzes those scans to quantify inflammation in tissue surrounding the arteries, while CaRi-Plaque assesses plaque and stenosis. The study combined those imaging measures with cardiometabolic profiling.

Biograph’s announcement says CaRi-Heart has received U.S. FDA De Novo marketing authorization and describes it as the first and only solution authorized to quantify coronary inflammation from routine CCTA. It says CaRi-Plaque has FDA clearance for AI-assisted plaque and stenosis analysis. Those regulatory descriptions concern the technologies; they do not establish the clinical benefit of using the inflammation result to guide care.

The company said the study manuscript is available as a preprint. A preprint is a research manuscript shared before or without completion of the journal peer-review process, so readers should distinguish the study’s reported results from findings independently confirmed through further research.

““42.9%” of participants exhibited elevated inflammation, and “17.9%” exhibited very high inflammation in at least one major heart artery.”

— Biograph study statement

Key Questions About the Results

The supplied announcement does not give the number of participants, study dates, full methods or detailed demographic breakdown, limiting readers’ ability to judge how representative the group was. It also does not provide enough information to assess the study’s statistical uncertainty or compare its participants with a wider population.

It remains unknown whether elevated perivascular inflammation predicts heart attacks or other cardiovascular outcomes, how consistently the AI measurement performs across different patient groups and imaging settings, or what level of inflammation should change clinical care. The reported lack of correlation with blood markers and a risk calculator is specific to this study and does not show that those tools have no value in cardiovascular prevention.

Biograph’s quoted commentary frames inflammation as a possible earlier phase of disease, but that interpretation is not established by the prevalence figures alone. Further research, including outcome studies and independent validation, is needed before the measure’s role in routine screening or treatment can be determined.

Validation and Outcome Research

The next steps are to examine the preprint’s full methods and data and to look for peer-reviewed publications or independent studies that test the finding in larger and more representative groups. Follow-up research would need to establish whether AI-detected inflammation predicts later cardiovascular events beyond existing measures.

Researchers would also need to assess whether care guided by the scan result changes outcomes, and weigh potential benefits against the costs and risks of additional imaging or follow-up. Until such evidence is available, the reported result is a study finding rather than a basis for readers to diagnose themselves or change treatment. Biograph’s announcement does not specify when further results will be released.

Key Questions

What does the 42.9% figure describe?

It is the share of participants in Biograph’s reported study who, according to the company, had elevated coronary inflammation on AI analysis of CCTA scans. It is not an estimate for all adults.

Does elevated inflammation mean a participant had blocked arteries?

No. Biograph said inflammation was also found in some participants with no detectable coronary plaque. The reported measure is not the same as a finding of blockage or a diagnosis of heart disease.

Did blood tests identify the participants with inflammation?

Biograph reported that the blood markers and cardiovascular risk calculator it assessed did not identify which participants had elevated inflammation. That conclusion applies to this study and does not establish that those tools are ineffective for other clinical purposes.

Does the study show that the AI scan prevents heart disease?

No. The announcement reports how often the study detected elevated inflammation, but does not show that the measure predicts future events or that treatment based on it improves health outcomes. The company said more research is needed.

Source: hn